Momecutan (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This down‑regulates pro‑inflammatory cytokines and up‑regulates anti‑inflammatory proteins, leading to decreased inflammation, reduced immune cell activity and relief of symptoms like redness and itching.

The dosage of Momecutan is individualized by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient age. The prescriber determines the amount, frequency and duration of application according to clinical guidelines.

Safety data for topical mometasone furoate in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare professional.

To request Momecutan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momecutan (mometasone furoate) is classified as a high‑potency topical corticosteroid, offering strong anti‑inflammatory effects with a favorable safety profile when used as directed. Compared with lower‑potency agents such as hydrocortisone, it provides faster symptom control, while its potency is similar to betamethasone dipropionate but may have lower systemic absorption when applied correctly.

Store Momecutan at room temperature, away from direct sunlight and moisture. Keep the product in its original packaging until use, and ensure the container is tightly closed after each application to maintain stability and potency.

Momecutan is applied topically to the affected skin area. The prescribed amount is gently spread in a thin layer, usually once or twice daily, and gently rubbed in until fully absorbed. Hands should be washed before and after application, and occlusive dressings should be avoided unless directed by a clinician.

Serious risks include skin atrophy, telangiectasia, and systemic adrenal suppression, especially when used over large body surfaces, for prolonged periods, or under occlusion. Patients should be monitored for signs of these effects, and therapy should be adjusted or discontinued if they occur.

Momecutan should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation components, in patients with untreated fungal, bacterial or viral skin infections, and in those where systemic corticosteroid therapy is contraindicated without medical supervision.